HANGZHOU TIGERMED CONSULTING CO., LTD Hangzhou Tigermed Consulting Co., Ltd Stock OTC Markets
Equities
HNGZY
US41044T1088
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.2 USD | -4.55% |
|
-.--% | -.--% |
| 04-25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
| 04-25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
| Sales 2024 * | 8.21B 1.13B 1.55B | Sales 2025 * | 9.92B 1.37B 1.87B | Capitalization | 43.69B 6.03B 8.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.03B 280M 382M | Net income 2025 * | 2.56B 354M 483M | EV / Sales 2024 * | 4.53 x |
| Net cash position 2024 * | 6.47B 893M 1.22B | Net cash position 2025 * | 8.85B 1.22B 1.67B | EV / Sales 2025 * | 3.51 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
18.3
x | Employees | - |
| Yield 2024 * |
0.93% | Yield 2025 * |
1.16% | Free-Float | 69.68% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -4.55% | ||
| 6 months | -46.02% |
1 year
4.20
4.40
3 years
4.2012.75
5 years
4.2012.75
10 years
4.2012.75
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Hao Wu
PSD | President | 56 | 19-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Bing Hui Zhang
CHM | Chairman | 61 | 20-04-27 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
China accounts for 46% of sales.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
53.93
CNY
Average target price
72.84
CNY
Spread / Average Target
+35.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- 300347 Stock
- HNGZY Stock
